Perceptive Advisors buys $110,198,741 stake in TESARO Inc (TSRO)

TESARO Inc (TSRO) : Perceptive Advisors scooped up 44,956 additional shares in TESARO Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 1,143,615 shares of TESARO Inc which is valued at $110,198,741.TESARO Inc makes up approximately 8.08% of Perceptive Advisors’s portfolio.

Other Hedge Funds, Including , Raymond James Associates boosted its stake in TSRO in the latest quarter, The investment management firm added 500 additional shares and now holds a total of 11,062 shares of TESARO Inc which is valued at $1,065,934.Blackrock Investment Management reduced its stake in TSRO by selling 11,471 shares or 9.06% in the most recent quarter. The Hedge Fund company now holds 115,081 shares of TSRO which is valued at $11,089,205. TESARO Inc makes up approx 0.01% of Blackrock Investment Management’s portfolio. Hap Trading added TSRO to its portfolio by purchasing 12,310 company shares during the most recent quarter which is valued at $1,149,385. TESARO Inc makes up approx 0.10% of Hap Trading’s portfolio.Sg Americas Securities reduced its stake in TSRO by selling 4,826 shares or 58.67% in the most recent quarter. The Hedge Fund company now holds 3,400 shares of TSRO which is valued at $323,578.

TESARO Inc closed down -6.33 points or -6.39% at $92.76 with 17,89,399 shares getting traded on Tuesday. Post opening the session at $98.8, the shares hit an intraday low of $91.83 and an intraday high of $98.8 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, TESARO Inc reported $-1.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.42 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-1.70. The company had revenue of $36.60 million for the quarter, compared to analysts expectations of $2.48 million. During the same quarter in the previous year, the company posted $-1.51 EPS.

Many Wall Street Analysts have commented on TESARO Inc. RBC Capital Mkts Initiated TESARO Inc on Aug 12, 2016 to “Outperform”, Price Target of the shares are set at $122.Company shares were Reiterated by Mizuho on Aug 5, 2016 to “Buy”, Firm has raised the Price Target to $ 100 from a previous price target of $94 .Company shares were Reiterated by Wedbush on Aug 5, 2016 to “Outperform”, Firm has raised the Price Target to $ 107 from a previous price target of $91 .

TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

TESARO Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on TESARO Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.